Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Accumulated Expenses (2016 - 2019)

Historic Accumulated Expenses for Bristol Myers Squibb (BMYMP) over the last 11 years, with Q1 2019 value amounting to $5.9 billion.

  • Bristol Myers Squibb's Accumulated Expenses rose 530.48% to $5.9 billion in Q1 2019 from the same period last year, while for Mar 2019 it was $5.9 billion, marking a year-over-year increase of 530.48%. This contributed to the annual value of $6.5 billion for FY2018, which is 789.82% up from last year.
  • Per Bristol Myers Squibb's latest filing, its Accumulated Expenses stood at $5.9 billion for Q1 2019, which was up 530.48% from $6.5 billion recorded in Q4 2018.
  • Bristol Myers Squibb's 5-year Accumulated Expenses high stood at $6.5 billion for Q4 2018, and its period low was $1.8 billion during Q1 2015.
  • Its 5-year average for Accumulated Expenses is $4.8 billion, with a median of $5.1 billion in 2017.
  • Per our database at Business Quant, Bristol Myers Squibb's Accumulated Expenses plummeted by 1031.55% in 2015 and then soared by 14070.35% in 2016.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's Accumulated Expenses stood at $4.7 billion in 2015, then grew by 11.25% to $5.3 billion in 2016, then rose by 14.1% to $6.0 billion in 2017, then grew by 7.9% to $6.5 billion in 2018, then decreased by 9.75% to $5.9 billion in 2019.
  • Its Accumulated Expenses stands at $5.9 billion for Q1 2019, versus $6.5 billion for Q4 2018 and $5.9 billion for Q3 2018.